Chronic Myeloid Leukemia After Chemoradiotherapy in a Patient with Non-Small Cell Lung Cancer
| Autor: | Demircioglu, Sinan, Ceneli, Ozcan, Bektas, Ozlen, Yilmaz, Seda, Korkmaz, Levent, Artac, Mehmet |
|---|---|
| Přispěvatelé: | Sinan Demircioğlu: 0000-0003-1277-5105, Özlen Bektaş: 0000-0002-2670-022X, Özcan Çeneli 0000-0003-2541-1335, Mehmet Artaç: 0000-0003-2335-3354, NEÜ, Meram Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalı |
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | International Journal of Hematology and Oncology. 27:256-257 |
| ISSN: | 1306-133X |
| DOI: | 10.4999/uhod.172012 |
| Popis: | WOS:000419586300008 Chronic myeloid leukemia(CML) is a myeloproliferative disease characterized by uncontrolled proliferation of mature and maturing granulocytes. Chronic myeloid leukemia accounts for approximately 15 to 20 percent of leukemias in adults. The incidence is 1-2/10000 per year.1-2 There is only one risk factor, which is ionized radiation.3 There are some publitions in the literature about CML development after chemotherapy and/or radiotherapy. Here we presented a case that CML occured after chemotherapy concurrent with radiotherapy in non-small cell lung cancer patient. Sixty year old man who has diagnosed inoperable lung adenocarcinoma in 2013. Carboplatin concurrent with radiotherapy was administered to him. After 2 years follow-up with no progression of disease, the level of leucocyte was started to increase. White blood cell level was 41700/ul, haemoglobin level was 14.3 g/dl and platelet level was 239000/ul. Peripheral blood smear suggested chronic myeloid leukemia. Bone marrow aspiration and biopsy was performed. The biopsy was supported chronic phase chronic myeloid leukemia. Cytogenetic analysis showed %95 translocation (9;22) in 20 metaphasis. BCR-ABL was detected as 60% IS. Sokal, Hasford and EUTOS risk score was calculated high. Imatinib therapy was started as 400 mg/day. Hematologic response was seen 2 weeks after imatinib treatment. After 3, 6, 12 months, BCR-ABL was detected as 27% IS, 1% IS, and 0.4 IS, respectively. The patient is still being followed as remission for both lung cancer and CML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|